Kane Biotech stock analysis
Want to see TSE:KNE full AI Analyst Report?
Kane Biotech (KNE) Stock Price & Analysis
KNE Stock Chart & Stats
- Day’s Range
- CAD 0.03 - CAD 0.03
- 52-Week Range
- CAD 0.02 - CAD 0.05
- Previous Close
- CAD 0.03
- Volume
- N/A
- Average Volume (3M)
- 53.42K
- Market Cap
- CAD 6.15M
- Enterprise Value
- CAD 7.26M
- Total Cash (Recent Filing)
- CAD 854.73K
- Total Debt (Recent Filing)
- CAD 1.96M
- Price to Earnings (P/E)
- ―
- Beta
- 0.64
- Next Earnings
- Nov 26, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Diversified Antibiofilm Platform
Kane’s antibiofilm technologies address several end markets rather than relying on one use case. This application breadth creates multiple avenues for commercialization and gives the company a platform from which successful formulations or products could support longer-term expansion.
Debt Reduction
Reducing total debt provides a modest improvement in financial flexibility and may lessen future interest or refinancing pressure. Although the balance sheet remains stressed, continued debt reduction can help preserve resources for operations and product commercialization over the next several quarters.
Improved Free Cash Flow Burn
The improvement in free cash flow versus 2025 indicates some movement toward better cash discipline, even though outflows remain substantial. If sustained, lower cash burn could extend the company’s operating runway and reduce the urgency of external funding for near-term activities.
Bears Say
Collapsing Revenue
Extremely low and declining revenue indicates that current commercial traction is insufficient to support the operating base. Persistent contraction reduces internally generated funding, limits reinvestment capacity, and makes the company more dependent on a successful recovery in product sales.
Severely Negative Margins
Margins at these levels show that current revenue is far below the cost required to deliver products and operate the business. Without a substantial improvement in pricing, sales scale, or cost structure, profitability is unlikely to become self-sustaining over the next several quarters.
Negative Equity And Solvency Pressure
A growing equity deficit is a significant balance-sheet weakness because liabilities exceed reported assets. It limits financial flexibility and raises the likelihood that future operations or investment could require refinancing or equity issuance, potentially constraining strategic choices.
Kane Biotech News
Kane Biotech to Spotlight revyve Biofilm Wound-Care Line at Wounds Canada Conference
An announcement from Kane Biotech ( ($TSE:KNE) ) is now available. Kane Biotech will showcase its U.S. FDA-cleared and Health Canada-approved revyve antimicrobial wound-care products at the Wounds Canada National
Kane Biotech Refreshes Brand and Website to Support Wound-Care Growth
An update from Kane Biotech ( ($TSE:KNE) ) is now available. Kane Biotech Inc., a Winnipeg-based biotechnology company, specializes in biofilm-disrupting technologies and advanced wound-care products designed to improve healing
KNE FAQ
What was Kane Biotech’s price range in the past 12 months?
What is Kane Biotech’s market cap?
When is Kane Biotech’s upcoming earnings report date?
How were Kane Biotech’s earnings last quarter?
Is Kane Biotech overvalued?
Does Kane Biotech pay dividends?
What is Kane Biotech’s EPS estimate?
How many shares outstanding does Kane Biotech have?
What happened to Kane Biotech’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Kane Biotech?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Kane Biotech
Headquartered in Winnipeg, Canada, Kane Biotech Inc. is a biotechnology firm established in 2001, focusing on the research, development, and global commercialization of innovative technologies and products engineered to prevent and remove microbial biofilms. The company's diverse portfolio features pet dental hygiene solutions marketed as StrixNB and bluestem, alongside DispersinB for both animal and human wound care. They also provide Alosera brand shampoos for dogs, cats, and horses, and Aledex for medical device coatings. Additional offerings include DermaKB scalp care products, Coactiv+ wound care items, and other specialized products under the goldstem, silkstem, and DermaKB Biofilm brand names.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Robert Huizinga
- Employees
- 32
- Website
- kanebiotech.com
- Address
- 290-100 Innovation Drive, Winnipeg, MB, R3T 6G2, CA
Kane Biotech (KNE) Earnings & Revenues
KNE Earnings Call
Earnings Call SentimentPositive
The earnings call highlighted significant revenue growth driven by new product sales and service revenue streams. Strategic partnerships, regulatory approvals, and expansion into new markets were noted as positive developments. However, increased operating expenses and a decrease in cash reserves were challenges mentioned. Overall, the positive developments notably outweigh the drawbacks.
View all TSE:KNE earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 5 | 11 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 3 | 0 | 9 |





